

References

E-58

1. Duncker D, Thorben Keonig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation. *J Am Heart Assoc.* 2017;6:e004512.
2. Reek S, Burri H, Roberts PR, Perings C, Epstein AE, et al. The wearable cardioverter-defibrillator: current technology and evolving indications. *Europace.* 2017;19:335–345.
3. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Ventricular arrhythmias in patients with newly diagnosed non-ischemic cardiomyopathy: Insights from the PROLONG study. *Clin Cardiol.* 2017;40(8):586-590.
4. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-The PROLONG Study. *J Am Heart Assoc.* 2017;6(1).
5. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation.* 2018;138(13).
6. Spar DS, Bianco NR, Knilans TK, et al. The US experience of the wearable cardioverterdefibrillator in pediatric patients. *Circ Arrhythm Electrophysiol.* 2018;11:e006163.
7. Clark MA, Szymkiewicz SJ, Volosin K. Mortality and costs associated with wearable cardioverter-defibrillators after acute myocardial infarction: A retrospective cohort analysis of Medicare claims data. *J Innovations in Card Rhythm Mgmt.* 2019;10(10): 3866-3873.
8. Sandhu U, Rajyaguru C, Cheung C, Morin D, Lee B. The wearable cardioverter-defibrillator vest: Indications and ongoing questions. *Progress CV Dis.* 2019;62: 256-264.
9. Olgin JE, Pletcher MJ, Vittinghoff E. et al. Wearable cardioverter-defibrillator after myocardial infarction. *NEJM.* 2018;379(13).
10. Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As treated and per protocol analyses. *J Cardiovasc Electrophysiol.* 2020;31:1009-1018.
11. Mueller_Leisse J, Brunn J, Zormpas C, et al. Extended follow-up after wearable cardioverter-defibrillator person: The PROLONG-II study. *ESC Heart Failure.* 2021;8(6):5142-5148.
12. Noriden Healthcare Solutions, LLC. LCD 33690. Effective 1/1/2020.